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AbstrAct
Background User- testing and subsequent modification 
of clinical guidelines increases health professionals’ 
information retrieval and comprehension. No study has 
investigated whether this results in safer care.
Objective To compare the frequency of medication errors 
when administering an intravenous medicine using the 
current National Health Service Injectable Medicines Guide 
(IMG) versus an IMG version revised with user- testing.
Method Single- blind, randomised parallel group in situ 
simulation. Participants were on- duty nurses/midwives who 
regularly prepared intravenous medicines. Using a training 
manikin in their clinical area, participants administered a 
voriconazole infusion, a high- risk medicine requiring several 
steps to prepare. They were randomised to use current 
IMG guidelines or IMG guidelines revised with user- testing. 
Direct observation was used to time the simulation and 
identify errors. Participant confidence was measured using 
a validated instrument. The primary outcome was the 
percentage of simulations with at least one moderate- 
severe IMG- related error, with error severity classified by an 
expert panel.
Results In total, 133 participants were randomised to 
current guidelines and 140 to user- tested guidelines. 
Fewer moderate- severe IMG- related errors occurred 
with the user- tested guidelines (n=68, 49%) compared 
with current guidelines (n=79, 59%), but this difference 
was not statistically significant (risk ratio: 0.82; 95% 
CI 0.66 to 1.02). Significantly more simulations were 
completed without any IMG- related errors with the user- 
tested guidelines (n=67, 48%) compared with current 
guidelines (n=26, 20%) (risk ratio: 2.46; 95% CI 1.68 to 
3.60). Median simulation completion time was 1.6 min 
(95% CI 0.2 to 3.0) less with the user- tested guidelines. 
Participants who used user- tested guidelines reported 
greater confidence.
Conclusion User- testing injectable medicines guidelines 
reduces the number of errors and the time taken to 
prepare and administer intravenous medicines, while 
increasing staff confidence.
Trial registration number researchregistry5275.
IntroductIon
Medication errors are a major cause of 
avoidable patient harm worldwide, with 
an estimated annual cost of $42 billion.1 
An estimated 237 million medication 
errors occur annually in England, 28% 
with potential to cause harm.2 Intravenous 
medicines are complex to prepare and 
more prone to error,3 4 with 35%–48% 
of intravenous doses erroneous in some 
way.3 4
Patient safety incidents have numerous 
causes, one of which is written guidance 
for health professionals that is contra-
dictory, incomprehensible or of poor 
quality.5 6 Specifically, medication errors 
have been caused by difficulty finding 
relevant, unambiguous information in 
guidelines.7–10 Two studies recommended 
that user- testing might improve medi-
cines guidelines for health professionals 
and thus improve safety,11 12 where user- 
testing assesses whether potential users 
of a document can find and understand 
important information. Problems are 
identified and potential solutions tested 
iteratively until the document is shown to 
perform well.11 13 14
User- testing has been shown to increase 
the amount of information found and 
understood by doctors using Summaries 
of Product Characteristics (SPC),11 and 
nurses using injectable medicines guide-
lines.12 Studies of patient- facing medi-
cines information, evidence summaries 
and infection control guidelines have also 
shown better understanding and faster 
reading time following user- testing.13 15–17 
However, no published study has inves-
tigated whether health professionals 
using user- tested guidelines make fewer 
medication errors, and thus provide safer 
patient care.
Our aim was to investigate the effective-
ness of user- testing of medicines guide-
lines for reducing medication errors. We 
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selected the administration of intravenous medicines 
by hospital nurses using the UK’s National Health 
Service (NHS) Injectable Medicines Guide (IMG),18 
due to the increased risk of medication errors with 
this route of administration.3 4 The IMG is designed 
to give guidance on the correct procedures for the 
preparation and administration of over 350 intrave-
nous medicines and is accessed online approximately 
3 million times per year.18 The majority of these 
users are nurses preparing and administering intrave-
nous medicines in clinical areas, who typically refer 
to the IMG as they work through each step of this 
process.12 However, a recent user- testing study identi-
fied that in 36 of 340 cases, nurses were unable to find 
or understand important information in the current 
IMG.12 After user- testing, numerous revisions were 
made to the guidelines, including provision of equa-
tions and tables to support dose, dilution and infusion 
rate calculations, additional subsections, and clearer 
wording and formatting (online supplementary file 3). 
Following these changes, the number of instances of 
nurses being unable to find or understand important 
information decreased to 3 of 340 cases. Therefore, 
the specific objective of the present study was to 
compare the frequency of medication errors made by 
nurses using current and user- tested IMG guidelines 
during the preparation and administration of an intra-
venous medicine.
Methods
study design
We conducted a single- blind, randomised parallel 
group in situ simulation experiment with a 1:1 allo-
cation ratio. Participants prepared and administered a 
simulated intravenous infusion of voriconazole, with 
observation used to identify medication errors. In situ 
simulation involves a simulated episode of patient 
care integrated into the clinical environment with 
participants who are on- duty health professionals. It 
is useful when it is not feasible to test interventions 
during routine care, but participants still experience 
the pressures and distractions present in the clinical 
environment.19
Participants and recruitment
Participants were on- duty nurses or midwives regis-
tered with the Nursing and Midwifery Council, who 
were authorised to prepare and administer intra-
venous medicines in their hospital and had done 
so during at least 50% of working shifts during the 
previous 6 months (or since authorisation if more 
recent) (self- assessed). They were recruited from four 
NHS acute hospital trusts between January and July 
2019. The managers of a range of different clinical 
departments (including medical and surgical inpatient 
wards, intensive therapy units, emergency depart-
ments, postanaesthetic care units and birthing units) 
agreed suitable times for simulations to take place 
and circulated written information about the study 
to their nursing staff. This informed potential partici-
pants that the study was investigating how changes to 
guidelines affect patient safety. At the agreed times, the 
researcher approached eligible staff currently working 
in the area and invited them to take part. Participation 
was voluntary and only occurred at a safe time for the 
participant’s patients. Therefore, to facilitate recruit-
ment, the researcher waited in each department until 
all interested staff had taken part.
definitions
An error was defined as any deviation from the simu-
lated medication order, the hospital’s policies or the 
IMG guidelines.3 20 21 Up to 30 errors were possible 
in a single simulation, regardless of the version of the 
guidelines used (structured observation forms, online 
supplementary file 2). An ‘IMG- related error’ was an 
error in a process that required use of information 
from the IMG. There were 11 types of IMG- related 
error, including use of incorrect fluids, fluid volumes 
or technique for reconstitution or dilution, adminis-
tration of an incorrect dose or at an incorrect rate and 
not flushing the intravenous cannula in accordance 
with hospital policy. All other errors were ‘non- IMG- 
related errors’, with five error types including selec-
tion of the wrong medicine, use of expired ingredients 
and breach of the hospital aseptic technique policy. 
Online supplementary file 3 presents definitions of 
error types. Deviations from procedures designed to 
reduce the likelihood of a subsequent error were not 
themselves included as errors, for example, labelling 
and documentation errors.21
simulated task
The simulation was carried out in the area of each 
participant’s usual clinical department designated for 
the preparation of intravenous medicines. This was 
most often a small room where medicines were stored 
and prepared, but empty bed spaces were used in some 
areas. These areas were still available to other users 
while the simulation was taking place.
Each participant worked alone to prepare one simu-
lated intravenous infusion of voriconazole in response 
to an inpatient medication order for a 360 mg (6 mg/
kg) adult loading dose, following the procedures they 
would normally employ. Voriconazole was chosen as it 
is classed as a high- risk medicine and requires a variety 
of intravenous procedures, including reconstitution, 
dilution and infusion at a controlled rate.18 Participants 
selected a vial from a box that contained 23 labelled 
placebo voriconazole vials (Dummy- Ject Powder C, 
MockMeds, Houston, Texas), 1 identical placebo vial 
labelled with another drug name and 1 identical vial of 
placebo voriconazole that had expired (as may occur 
in practice). Images of the vials and labels are shown in 
online supplementary file 2. All other equipment was 
taken from routine stock in the participant’s clinical 
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area. Participants then administered this one dose to 
an intravenous training manikin arm (Multi- Venous, 
Laerdal Medical, Orpington, UK).
Participants were randomised to use one of two 
versions of the IMG guidelines for voriconazole on a 
laptop computer. The control group used the version 
of the guidelines used in practice (‘current guide-
lines’). The other group used a version of the guide-
lines revised through three rounds of user- testing with 
hospital nurses (‘user- tested guidelines’), as described 
above.12 Both versions contained the same informa-
tion, presented in different ways (online supplementary 
file 1). To prevent participants using prior knowledge, 
the drug name ‘voriconazole’ was changed to ‘bathi-
cillin’ in all study documents and labels. Brand names 
were also changed. The descriptions of the strength 
of one vial, its displacement volume and the required 
volume of reconstituting fluid were adjusted in the 
IMG guidelines to match the available placebo vials. 
References to the compulsory use of an infusion pump 
were removed, as this equipment was not consistently 
available. Therefore, participants could correctly 
administer an infusion using either an infusion pump 
or a gravity infusion set (infusion rate calculated from 
drip rate).
Participants were given no directions on how to use 
the guideline, but were asked to follow their usual 
practice. However, as ‘bathicillin’ was an unknown 
medicine for all participants, the allocated guideline 
was their only potential source of information on how 
to correctly prepare and administer the dose.
data collection
Initially, participant characteristics were documented 
to confirm eligibility. Then participants prepared and 
administered their dose while being observed by one 
researcher (MDJ) who noted preparation or admin-
istration errors on a structured form (online supple-
mentary file 2). Observation is considered the most 
robust method for quantifying medication administra-
tion errors.3 20 22 23 The time taken to complete the 
simulation was recorded, from when the participant 
opened their IMG guideline to when they informed 
the researcher they would leave the simulated patient’s 
bedside after starting the infusion. After finishing the 
simulation, each participant completed a modified 
version of the Provider Decision Process Assessment 
Instrument (mPDPAI) questionnaire to measure their 
perceived degree of knowledge and uncertainty during 
the simulation.24 Modifications included removing 
questions 6, 8, 9 and 10 from the original instru-
ment, as these related to concepts not relevant in this 
context. The remaining questions were reworded to 
focus on a series of decisions on how to prepare and 
administer voriconazole (online supplementary file 
2). To investigate the psychometric properties of the 
mPDPAI, participants also answered quality and satis-
faction validation questions.24 Finally, each participant 
was shown both versions of the IMG guidelines and 
asked to review them for as long as they wished (typi-
cally 1–2 min) before stating which they preferred, 
using a 7- point scale ranging from strongly preferring 
the current guidelines to strongly preferring the user- 
tested guidelines (online supplementary file 2).
To investigate the reliability of the observations, 10% 
of simulations were recorded using a video camera 
(Akaso EK7000) mounted on the participant’s fore-
head. This recorded images of wherever the partici-
pant looked, including medicine preparation. Videos 
were viewed independently by a second researcher, 
using the same structured form to record errors.
error severity classification
The potential severity of each observed error was 
assessed using a validated method appropriate for situ-
ations where actual patient outcome is unknown.3 4 25 
A panel was established, comprising two consultant 
physicians, three hospital pharmacists and two hospital 
nurses (minimum 10 years of experience). Each panel 
member was sent a brief description of each error and 
asked to score its potential clinical significance on a 
scale from 0 (no harm) to 10 (death). The panel was 
informed that incidents related to an adult weighing 
60 kg prescribed a 6 mg/kg loading dose (360 mg) of 
voriconazole for administration by intravenous infu-
sion over 2–3 hours. They were asked to assume that 
the patient was on a general medical or surgical ward 
with peripheral venous access. As a full clinical history 
was not available, they were asked to rate the poten-
tial clinical significance for a typical patient prescribed 
voriconazole. To investigate the validity of this 
process, the panel also scored 15 injectable medica-
tion errors with a known outcome from the literature 
(five each with known minor, moderate and severe 
outcomes).26–30 The mean panel score for each error 
was calculated and used to classify it as either a minor 
(mean score <3), moderate (mean score 3–7) or severe 
error (mean score >7).
outcomes and sample size
The primary outcome was the observed frequency of 
simulations with one or more IMG- related moderate- 
severe errors. Frequencies were expressed as percent-
ages using the number of simulations considered to 
have one or more errors as the numerator and the 
total number of simulations as the denominator.3 4 
Where multiple errors were observed within the same 
simulation, the severity of the most serious error 
was assigned to the simulation. Secondary outcomes 
were the frequency of simulations with one or 
more moderate- severe non- IMG- related errors, the 
frequency of simulations without any IMG- related 
errors and the frequency of simulations without any 
non- IMG- related errors, as well as the time taken to 
complete the simulation, a decisional conflict score 
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(DCS) derived from mPDPAI responses (see the Anal-
ysis section) and guideline preference.
Assuming a frequency of moderate- severe IMG- 
related errors of 30% in the ‘current guidelines’ 
group,3 4 a clinically relevant reduction to 15% in the 
‘user- tested guidelines’ group, a 5% significance level, 
80% power and no clustering by hospital, a sample size 
of 121 participants/group was calculated.31 A power 
calculation accounting for clustering by hospital gave 
a sample size of 172 participants per group for four 
NHS trusts (based on similar assumptions and an 
intraclass correlation coefficient of 0.01). Therefore, 
a minimum sample size of 121 participants per group 
was adopted, with a maximum of 172 participants per 
group.
randomisation and blinding
The allocation sequence was generated by an inde-
pendent researcher using an online blocked randomi-
sation list generator ( www. sealedenvelope. com/ simple- 
randomiser/ v1/ lists) (block size of 10). Allocation was 
stratified by research site and participant experience 
(<5 or ≥5 years of accreditation for the administration 
of intravenous medicines). The researcher enrolled 
and then allocated participants immediately prior to 
their simulation using an online randomisation service 
( www. sealedenvelope. com). This generated a unique 
code, which identified the computer file containing 
the participant’s IMG guideline.
The researcher was blinded to participant allocation 
by the use of a privacy filter on the laptop computer 
screen. This permitted only a reader directly in front 
of the screen to see the information displayed. The 
laptop computer was angled away from the researcher, 
so he was unable to see the IMG guideline. Data anal-
ysis was conducted using blinded conditions.
Analysis
Statistical analysis was performed using SPSS (V26) 
and STATA. Only data from completed simulations 
were included in the analysis. Participants were 
analysed in the group to which they were allocated. 
The inter- rater reliability between the live and video 
observations was quantified using Cohen’s kappa, with 
each step on the observation form constituting a data 
point (error vs no error).32 The inter- rater reliability of 
the severity scoring panel was calculated using Cron-
bach’s alpha.33 The validity of the scores was investi-
gated by comparing the mean severity scores of the 
literature errors with their known outcomes.
The median time taken to prepare and set up the 
infusion in the two groups was calculated using the 
Kaplan- Meier estimator. This accounted for censored 
simulations, defined as participants being unable 
to finish the simulation without assistance from a 
colleague.
mPDPAI responses were used to calculate a modi-
fied DCS (mDCS) for each participant, following the 
methods described for the original PDPAI.24 Theoret-
ically, mDCS could range from 8 to 40, with a higher 
score reflecting greater uncertainty while preparing 
and administering voriconazole. The psychometric 
properties of the mPDPAI were investigated using 
the methods used during the initial development of 
the PDPAI.24 Item homogeneity was evaluated by 
calculating Spearman’s rank correlation coefficients 
between each item and a revised mDCS calculated 
by removing that item from the total score. Interitem 
reliability was investigated by the calculation of Cron-
bach’s alpha. Construct validity was investigated by 
hypothesising that there would be negative correlations 
between the mDCS and participants’ self- rating of the 
quality of their dose of voriconazole, and between the 
mDCS and how participants would feel if every intra-
venous drug administration was like the simulation.24 
This was investigated by calculating Spearman’s rank 
correlation coefficients between participants’ mDCS 
and their responses to the quality and satisfaction 
validation questions. It was also hypothesised that 
nurses who are more uncertain would take longer 
to complete the simulation. This was investigated by 
calculating the Spearman’s rank correlation coefficient 
between mDCS and time taken to complete the in situ 
simulation. Finally, it was hypothesised that nurses 
who are more uncertain were more likely to make 
an IMG- related error. This was investigated using a 
logistic regression of the presence or absence of IMG- 
related errors for each participant with the mDCS as 
a variable.
Responses to the guideline preference rating scale 
were compared between the two groups using a χ2 
test. Due to small expected counts, responses for the 
categories ‘Strongly prefer current guidelines’, ‘Prefer 
current guidelines’ and ‘Somewhat prefer current 
guidelines’ were combined.
Multivariate analysis was carried out to determine 
the influence of the allocated IMG guideline on the 
study outcomes while adjusting for participant char-
acteristics: first language (English or not), experience 
administering intravenous medicines (more or less 
than 5 years), current use of the IMG (regular or not) 
and NHS trust. The frequency of errors was inves-
tigated using logistic regression with model- based 
estimates used to convert the ORs to risk ratios, to 
aid interpretation. Simulation completion times were 
investigated using a Cox proportional hazards model 
and mDCS using multiple linear regression. For all 
outcomes, both mixed effects models (with NHS trust 
as the random effect and other characteristics as fixed 
effects) and fixed effects models were investigated. 
Models were checked for fit and results from the best 
fitting models presented.
results
In total, 273 participants completed the simulation 
before recruitment ended with all willing participants 
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Figure 1 Flow diagram of participant progress through the phases of this randomised in situ simulation experiment.
Table 1 Characteristics of participants who completed the simulation (n=273)
Current guidelines (n=133) User- tested guidelines (n=140)
Number of female participants (% within group) 116 (87) 125 (89)
Mean age (SD) 35.9 (10.3) 35.3 (10.7)
Median years nursing experience (IQR) 7.0 (4.0–14.0) 8.5 (3.0–14.8)
Median years authorised to give intravenous medicines (IQR) 6.5 (3.0–12.0) 6.8 (3.0–13.4)
Median percentage of shifts in which intravenous medicines administered (IQR) 100 (90–100) 100 (95–100)
Number with English as first language (% within group) 109 (82) 105 (75)
Previous experience of the NHS Injectable Medicines 
Guide (% within group)
Regular user 91 (68) 98 (70)
Past user 12 (9) 14 (10)
Seen 21 (16) 14 (10)
Not seen 9 (7) 14 (10)
Number of participants from each NHS trust
(% within group)
1 43 (32) 43 (31)
2 25 (19) 25 (18)
3 36 (27) 41 (29)
4 29 (22 31 (22)
NHS, National Health Service.
recruited and the minimum sample size achieved 
(figure 1). Two participants withdrew due to anxiety 
and three due to unexpected additional work. Partic-
ipant characteristics were similar in the two groups 
(table 1). In total, 189 participants (69%) reported 
being regular users of the current guideline format. 
Some participants were observed to read their 
allocated guideline, gather equipment and plan their 
work before starting to prepare the dose, whereas 
other participants read the guideline concurrently with 
working through the task.
Cohen’s kappa for the comparison of live and video 
observations (28 simulations) was 0.90, indicating 
high agreement.32 There was high agreement among 
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Table 2 Errors observed during simulation study, categorised by potential severity and error type
Error code* Error type
Current guidelines (control)
(n=133 simulations)
User- tested guidelines
(n=140 simulations)
Minor Moderate Severe Total Minor Moderate Severe Total
Number of IMG- related errors
I1 Wrong reconstituting fluid 0 0 0 0 0 0 0 0
I2 Wrong reconstituting fluid volume 1 0 0 1 0 0 0 0
I3 Dose discrepancy 13 16 0 29 4 6 0 10
I4 Wrong diluent 0 0 0 0 0 1 0 1
I5 Wrong diluent volume 0 6 0 6 0 0 0 0
I6 Incorrect technique (IMG related) 1 55 0 56 6 58 0 64
I7 Wrong route 0 0 0 0 0 0 0 0
I8 Flush error 0 12 0 12 0 12 0 12
I9 Rate discrepancy 10 30 0 40 1 12 0 13
I10 Infusion expiry error 0 0 0 0 0 0 0 0
I11 Other IMG- related error† 23 4 5 32 1 2 1 4
Total IMG- related errors 48 123 5 176 12 91 1 104
Number of non- IMG- related errors
N1 Wrong medication 0 5 0 5 0 6 0 6
N2 Incorrect technique (non- IMG related) 64 34 0 98 69 52 0 121
N3 Non- aseptic technique 264 194 0 458 289 220 0 509
N4 Expired ingredient 0 5 0 5 0 2 0 2
N5 Other non- IMG- related error 10 0 0 10 9 1 0 10
Total non- IMG- related errors 338 238 0 576 367 281 0 648
*Error codes cross- reference to the observation recording forms shown in online supplementary file 2 and online supplementary file 3, table 4.
†Other IMG- related errors consisted of participants who were not confident to finish the simulation without assistance from a colleague and composite 
errors where a participant gave the dose as a short injection, so it was both undiluted and administered too quickly.
IMG, Injectable Medicines Guide.
the expert panel (Cronbach’s alpha 0.93) regarding 
the clinical significance of errors. For 13 of 15 inject-
able medication errors with a known outcome from 
the literature, the mean potential clinical significance 
score was equivalent to their known outcome. For 
one error with a known severe outcome (equivalent 
to a mean potential clinical significance score >7), the 
mean potential clinical significance score was 6.6. For 
another with a known minor outcome (equivalent to 
a mean potential clinical significance score <3), the 
mean potential clinical significance score was 5.7. The 
item homogeneity, interitem reliability and construct 
validity of the mPDPAI were all high (online supple-
mentary file 3).
In total, 1504 errors were observed (table 2) and 
267 of 273 simulations (98%) included at least one 
error of any type. For the primary outcome, although 
a smaller proportion of the simulations with the 
user- tested guidelines (49%) included at least one 
moderate- severe IMG- related error than with the 
current guidelines (59%), the risk ratio of 0.82 (95% 
CI 0.66 to 1.02) did not indicate a significant differ-
ence (table 3). However, the proportion of user- tested 
guideline simulations without any IMG- related errors 
(48%) was significantly greater than with the current 
guidelines (20%), with a risk ratio of 2.46 (95% CI 1.68 
to 3.60). This indicates that when using the user- tested 
guidelines, a simulation was more than twice as likely 
to have no IMG- related errors than when using the 
current guidelines. Risk ratios indicate no significant 
differences between the groups for non- IMG- related 
errors (table 3).
Median completion time for the simulation was 
1.6 min (95% CI 0.2 to 3.0) faster with the user- tested 
guidelines (table 3), indicating a statistically significant 
decrease in completion time. There was a statistically 
significant 45% increase in the chance of completing 
the simulation if using the user- tested guidelines 
compared with the current guidelines (HR 1.45, 95% 
CI 1.11 to 1.89). Online supplementary file 3, figure 
3 shows the Kaplan- Meier curve for these data. The 
mDCS suggest that participants allocated the user- 
tested guidelines reported more confidence in their 
knowledge of how to prepare and administer intra-
venous voriconazole. The mDCS multiple regression 
coefficient indicates that on average, participants using 
the user- tested guidelines had an mDCS of 9.83 less 
than those using current guidelines, which is a substan-
tial proportion of a scale that has a maximum range 
of 32 points (8–40). After comparing both versions of 
the guidelines, 129 participants allocated the current 
guidelines (97%) and 122 participants allocated the 
user- tested guidelines (87%) expressed at least some 
preference for the user- tested guidelines (figure 2). 
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Table 3 Primary and secondary outcomes by group
Current guidelines 
(control) (n=133)
User- tested guidelines 
(n=140) Multivariate analyses*
Number of simulations with one or more moderate- 
severe IMG- related errors (% within group)
79 (59) 68 (49) RR: 0.82†‡
(95% CI 0.66 to 1.02)
Number of simulations with one or more moderate- 
severe non- IMG- related errors (% within group)
109 (82) 124 (89) RR: 1.09†§
(95% CI 0.98 to 1.20)
Number of simulations without any IMG- related 
errors (% within group)
26 (20) 67 (48) RR: 2.46‡
(95% CI 1.68 to 3.60)
Number of simulations without any non- IMG- 
related errors (% within group)
11 (8) 6 (4) RR: 0.45§
(95% CI 0.19 to 1.30)
Median minutes taken to prepare and set up 
infusion (95% CI)
13.0 (12.2 to 13.8) 11.4 (10.5 to 12.2) HR: 1.45‡
(95% CI 1.11 to 1.89)
Median modified decisional conflict score (IQR)¶ 27 (18–32) 16 (13–18) MRC: −9.83‡
(95% CI −11.36 to −8.32)
*Multivariate analyses compare outcomes for the user- tested guidelines relative to outcomes for the current guidelines. They were adjusted for participant 
characteristics: first language (English or not), experience administering intravenous medicines (more or less than 5 years), current use of the IMG (regular 
or not) and National Health Service (NHS) trust.
†Only NHS trust included as covariate. Other participant characteristics did not improve fit of the model.
‡NHS trust included in model as random effect.
§NHS trust included in model as fixed effect.
¶The modified decisional conflict score (mDCS) can range from 8 to 40, higher numbers represent greater uncertainty.
IMG, Injectable Medicines Guide; MRC, multiple regression coefficient; RR, risk ratio.
Figure 2 Number of participants expressing different levels of 
preference for either the current guidelines (CG) or user- tested guidelines 
(UTG).
This difference between the two groups was statisti-
cally significant (p<0.001; χ2 test).
dIscussIon
This study is the first to investigate whether user- testing 
of guidelines results in safer medication administration. 
There was no significant difference in the frequency of 
moderate- severe medication errors. However, use of 
user- tested guidelines more than doubled the proba-
bility of avoiding an IMG- related error during prepa-
ration and administration of an intravenous medicine 
on hospital wards. The procedure was also completed 
faster with user- tested guidelines, as participants were 
able to locate the information they required more 
quickly. Nurses felt more confident about their deci-
sions when using user- tested guidelines and preferred 
them to the original version.
The guideline revisions likely to have contributed 
to the reduced frequency of errors after user- testing 
can be identified by considering the error types with 
the largest reduction (table 2). These include dose and 
rate discrepancies (including administration by short 
injection rather than infusion), suggesting that the 
improved support for dose, rate and dilution calcula-
tions in the user- tested guidelines (eg, equations and 
tables)12 at least partially contributed to safer and faster 
preparation and administration of the medicine. This 
is consistent with the findings of our previous study, 
where dose and rate calculation problems occurred 
more often with the current guidelines than with the 
user- tested guidelines.12 A common calculation error 
with the current guidelines was not accounting for 
displacement volume when measuring the volume 
of drug solution containing the prescribed dose. The 
user- tested guidelines helped prevent this error by 
providing an equation for this calculation. A common 
rate discrepancy with the current guidelines was to 
administer the infusion over 1 hour. The instructions 
stated ‘give over 1–3 hours (maximum rate 3 mg/kg/
hour)’, and some participants used the first time listed 
(1 hour) rather than calculating the maximum infusion 
rate based on the second part of this instruction (3 mg/
kg/hour=2 hours). The user- tested guidelines did not 
present this range of infusion times (which was only 
applicable to some doses) and instead provided a table 
of infusion lengths and an equation to support the 
calculation, thus preventing this error. This suggests 
that guideline authors should provide equations and 
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tables to support health professionals making calcula-
tions. However, as different ways of presenting infor-
mation may be successful in different contexts, the 
safety improvements suggested by this study will be 
best achieved through user- testing.
These results build on previous findings by demon-
strating for the first time that user- tested guidelines can 
change the actions of nurses and thus result in fewer 
errors. In contrast, previous research has focused on 
health professionals’ comprehension of information. 
A randomised study found that a user- tested version 
of a Cochrane review improved participants’ satis-
faction and correct comprehension of key results, 
while decreasing reading time.15 Similar results were 
obtained from a non- randomised study of user- tested 
infection control guidelines.16 The only previous 
studies of medicines guidelines have shown that user- 
testing improves the retrieval and comprehension of 
information from documents such as SPCs11 and the 
IMG used in this research.12
Among the strengths of this study are its blinded, 
randomised design and the ‘anonymisation’ of the drug 
name in the IMG guidelines to prevent use of prior 
knowledge. Data were collected from nurses working 
in their usual clinical environment, thus ensuring a 
high- fidelity simulation in which participants in both 
groups were exposed to typical work pressures and 
distractions. The validity and reliability of the error 
observation process, the potential clinical significance 
scores and the mPDPAI were also confirmed.
Limitations include use of simulation rather than 
the investigation of actual patient care, which may 
have changed participants’ practice. In particular, the 
study simulated a nurse preparing and administering 
an unfamiliar medicine for the first time. In day- to- day 
practice, nurses are familiar with most of the medi-
cines they handle, which might reduce both the risk 
of error and the effect of a user- tested IMG guideline. 
In addition, to ensure internal validity, nurses were 
not permitted to ask a colleague for assistance during 
the simulation and the dose was not double- checked. 
However, double- checking of intravenous medicines is 
a commonly adopted practice in UK hospitals to reduce 
the risk of medication errors, in spite of insufficient 
evidence of its effectiveness.34 As nurses were directly 
observed, the Hawthorne effect may also have affected 
their practice and the unfamiliar format of the user- 
tested guidelines may have caused participants to pay 
more attention, although evidence suggests that obser-
vation does not affect the validity of observational 
methods for identifying medication administration 
errors.22 These factors (especially the unfamiliarity of 
the medicine) may explain the high frequency of errors 
observed in this study (98% of simulations included 
at least one error of any type) compared with system-
atic reviews of direct observation studies that have 
reported error frequencies of 35%–48% in subanal-
yses of intravenous doses (excluding dose timing 
errors).3 4 Therefore, the absolute error frequencies 
observed in this study may not be generalisable to 
day- to- day practice. However, the relative difference 
in error frequencies between the two groups can be 
considered generalisable (as both groups were treated 
equally), particularly in relation to the administration 
of unusual or complex medicines in NHS hospitals. 
Finally, blinding was often inadvertently broken by 
what participants said and did. However, blinding was 
restored during data analysis.
These results suggest that the user- tested format 
of the IMG should be adopted and that IMG guide-
lines should be user- tested. However, the results also 
have wider implications, suggesting all health systems 
should consider adopting user- testing for medicines 
guidelines, particularly those that address high- risk 
and complex decisions. This will ensure that in addi-
tion to being accurate, such guidelines are also usable 
for their target readership, resulting in a potential 
improvement in patient safety.12
Future research should aim to measure the effects 
of user- tested guidelines on actual patient care, for 
example, by focusing on the implementation of the 
user- tested format of the IMG. In addition, the effects 
of user- testing have only been examined for two types 
of medicines guidelines (SPCs and the IMG), and 
further investigation of its effects on other types of 
guideline in various healthcare settings is required.
conclusIon
A user- tested injectable medicines guideline reduced 
the number of errors and the time taken during the 
preparation and administration of intravenous medi-
cines. It also resulted in greater confidence and prefer-
ence among nurses. User- testing has the potential to be 
widely applied to other types of medicines guidelines, 
with anticipated improvements in patient safety.
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